Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Celgene
Summit, New Jersey, United States of America
- Ownership
- Public · BMY
- Development stage
- Other
01
Overview
Celgene has successfully developed multiple commercial products including Revlimid, Pomalyst, Thalomid, and Abraxane. Revlimid generated $8.2 billion in 2017, Pomalyst generated $1.6 billion, and Otezla generated $1.3 billion in 2017.
- Therapeutic areas
- OncologyImmunologyDermatologyRheumatology
- Modalities
- Small moleculesProtein regulation therapiesGene regulation therapies
- Industry
- Pharma
02
Partnerships
Rockefeller University
Beyond the preview
Go deeper on Celgene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celgene.